checkAd
    EyePoint Pharmaceuticals Aktie
    ISIN: US74440J1016 · WKN: A0Q4DQ · USA

    Neueste Nachrichten

    EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
    05.06.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.05.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
    08.05.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy
    06.05.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.04.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
    02.04.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    18.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
    07.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
    04.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
    29.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
    27.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.02.24 · globenewswire · EyePoint Pharmaceuticals